Cancer clinical trials in the region Occitanie
385 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Amyloidosis
#NCT06158854
Required histologic types
AL Amyloidosis
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Monoclonal antibodies
Proteasome inhibitor
Required organ involvement status
Presence
Required Mayo Clinic stages
Stade I
Stade II
Stade IIIA
Excluded previous treatments
Systemic Treatment-Naive
2 recruiting sites
Abbvie
Phase 1 / Phase 2
Lung cancer
#NCT06567015
#2023-510203-21-00
Partie 2 (Optimisation de la dose)
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Laboratoires Pierre Fabre
Phase 1 / Phase 2
Lung cancer
#NCT06567015
#2023-510203-21-00
Partie 1 (Escalade de dose et Backfilling)
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Laboratoires Pierre Fabre
Phase 1 / Phase 2
Lung cancer
#NCT06892548
#2024-520238-31-00
Partie 2 - Cohorte 7
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
BioNTech SE
Phase 1 / Phase 2
Lung cancer
#NCT06892548
#2024-520238-31-00
Partie 2 - Cohorte 1 et 4
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
BRAF
EGFR
HER2
KRAS G12C
MET
NTRK-1/2/3
RET
ROS-1
Excluded previous treatments at localized stage
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Antibody Drug Conjugates (ADC)
4 recruiting sites
BioNTech SE
Phase 1 / Phase 2
Lung cancer
#NCT06892548
#2024-520238-31-00
Partie 2 - Cohortes 3 et 5
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded genetic anomalies
ALK
BRAF
EGFR
HER2
KRAS G12C
MET
NTRK-1/2/3
RET
ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
BioNTech SE
Phase 1 / Phase 2
Lung cancer
#NCT06892548
#2024-520238-31-00
Partie 2 - Cohorte 6
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ALK
BRAF
EGFR
HER2
KRAS G12C
MET
NTRK-1/2/3
RET
ROS-1
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
BioNTech SE
Phase 1 / Phase 2
Lung cancer
#NCT06892548
#2024-520238-31-00
Partie 2 - Cohorte 2
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
BioNTech SE
Phase 1 / Phase 2
Lung cancer
#NCT06892548
#2024-520238-31-00
Partie 1 (Escalade de dose)
Required histologic types
SCLC (Small Cell Lung Cancer)
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
BioNTech SE
Phase 1 / Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
Head and neck cancer
Sarcoma and GIST
Thymus cancer
Penile cancer and germ cell tumors
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
#NCT06128551
Phase 1b extension de dose et phase 2 cohortes tumeurs solides naïves d'inhibiteurs de KRAS G12C
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Targeted therapy
7 recruiting sites
Revolution Medicines, Inc.